CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel

The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products from GSK, Moderna, and Pfizer.

The decision follows guidance issued initially by its advisory panel in April, before the group was removed by U.S. Health Secretary Robert F. Kennedy Jr.

Adults aged 50 to 59 who are at higher risk of severe illness from RSV are now advised to receive a single dose of vaccine, according to a Reuters report. Previously, the CDC’s guidance covered only people over 75 or high-risk adults between the ages of 60 and 74. 

Three RSV vaccines have FDA approval in the U.S., including GSK’s Arexvy, Moderna’s mRESVIA, and Pfizer’s Abrysvo.

The agency also endorsed GSK’s new five-in-one meningococcal vaccine for healthy 16- to 23-year-olds, as well as high-risk individuals aged 10 and older. 

They were adopted in the absence of a permanent director of the CDC. President Donald Trump’s pick for the post, Susan Monarez, is still awaiting Senate confirmation.

In May, the CDC also accepted the Advisory Committee for Immunization Practices’ (ACIP) earlier recommendation to approve a chikungunya vaccine — a move that, like other CDC decisions, helps guide what doctors offer and what insurance will cover.

More recently, a revamped vaccine advisory panel, established by Robert F. Kennedy Jr., met in June and called for seasonal flu shots to exclude thimerosal, a mercury-based preservative that has been considered safe for decades. 

The new panel is also expected to review the vaccination schedule for children and teens in the coming months.

On Stocktwits, retail sentiment was ‘bullish’ for both Pfizer and GSK, with message volume marked as ‘high’ for Pfizer and ‘low’ for GSK by late Wednesday. Meanwhile, Moderna saw ‘extremely bullish’ sentiment alongside ‘high’ message volume.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on